OPKO Health, Inc. (OPK)

Market Cap	1.24B +9.2%
Revenue (ttm)	587.90M -11.5%
Net Income	-72.89M
EPS	-0.09
Shares Out	746.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,471,200
Open	1.380
Previous Close	1.240
Day's Range	1.370 - 1.680
52-Week Range	0.977 - 1.680
Beta	1.48
Analysts	Buy
Price Target	4.38 (+163.86%)
Earnings Date	Jul 27, 2026

About OPK

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1995
• Employees: 2,275
• Stock Exchange: NASDAQ
• Ticker Symbol: OPK
• Website: https://www.opko.com

Financial Performance

In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for OPK stock is "Buy." The 12-month stock price target is $4.38, which is an increase of 163.86% from the latest price.

Price Target

$4.38

(163.86% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 28, 2026

Data Sources Report a data error